Pa. Pharma Ruling Opens New Front In Mass Tort Battles

Law360, Philadelphia (January 23, 2014, 7:00 PM ET) -- A Pennsylvania Supreme Court ruling that pharmaceutical companies can be held liable for negligence in the design and marketing of drugs delivers a substantial new tool to plaintiffs in a state known as a hotbed for mass tort litigation, experts said Thursday.

The court on Tuesday rejected Pfizer Inc. subsidiary Wyeth Ltd.’s premise that under Pennsylvania law, pharmaceutical companies had immunity from all negligence claims beyond the two areas it was willing to concede: manufacturing defects and inadequate warnings. Plaintiffs attorneys cast the high court’s 4-2 decision in a...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required